PG
ABBV icon

Portola Group’s AbbVie ABBV Stock Holding History

Portola Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$1.42M Buy
+21,200
New +$1.38M 1.88% 14

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Portola Group's ABBV Position: Q2 2015 in Review

Portola Group opened a new position in AbbVie (ABBV) in Q2 2015: 21,200 shares worth $1.42M. The stake represents 1.88% of the portfolio and ranks #14 among its holdings.

1,652 funds tracked by Wall St. Rank hold ABBV as of Q2 2015.

  • Portola Group held 21,200 shares of AbbVie worth $1.42M as of Q2 2015.
  • AbbVie was a new Portola Group position in Q2 2015.
  • AbbVie made up 1.88% of Portola Group's portfolio in Q2 2015, its #14 holding.
  • 1,652 funds tracked by Wall St. Rank held AbbVie as of Q2 2015.

Based on Portola Group's 13F filing for Q2 2015, filed 17 Jul 2015.